This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.
In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved greater blood glucose reductions compared to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), Boehringer Ingelheim and Eli
shrug off a 12% decline for diabetes treatment Januvia (sitagliptin) on pricing pressure.
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's DPP-4 inhibitor Januvia(sitagliptin), Boehringer Ingelheim and Eli Lilly's SGLT2
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's Januvia (sitagliptin) Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) and
Chief executive Ken Frazier took pains to point to other growth spots in MSD’s portfolio, particularly as diabetes blockbuster Januvia (sitagliptin) showed signs of weakness again after a return to
savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens), Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).
More from news
Approximately 8 fully matching, plus 88 partially matching documents found.
The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...